Recent blockbuster wins suggest global drug makers aren’t just succeeding through long-term research. Companies have repeatedly found success by bringing pipeline compounds back from the discard pile, turning old bets into major drugs and vaccines. While strategy still matters, the pattern points to luck playing an outsized role in which therapies finally reach patients.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
